Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancer
Yixin Chen(Jinan University), Ai‐Ming Yu(University at Buffalo, State University of New York), Fangwei Han(Liaoning Technical University), Neelu Batra(University of California, Davis), Primo N. Lara(UC Davis Comprehensive Cancer Center), Zhenzhen Liu(Zhengzhou University), Mei‐Juan Tu(University of California, Davis), Hong-Wu Chen(University of California, Davis), Huichang Bi(Southern Medical University)
Cited by 14
Related Papers
Current trends in drug metabolism and pharmacokinetics
|Acta Pharmaceutica Sinica B|2019|391
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2011|320
Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC
|Journal of Thoracic Oncology|2018|236
RNA therapy: Are we using the right molecules?
|Pharmacology & Therapeutics|2018|172